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INTRODUCTION1 
With imaging demand ever increasing and the expectation for rapid access to imaging growing, 
opportunities to streamline processes are of interest to both health professionals and administrators.  
As with all investigations, radiologists and radiographers retain the responsibility to ensure that 
patient safety is not compromised as a result of quicker turnaround, both from a radiation perspective 
                                                          
Abbreviations 
CKD-EPI  Chronic kidney disease – epidemiology collaboration equation 
CSW  Clinical Support Worker 
eGFR  Estimated glomerular filtration rate 
PoC  Point of Care 
PC-AKI  Post contrast acute kidney injury 
QC  Quality control 
SCr  Serum creatinine 
WBCr  Whole blood creatinine 
 
2 
 
and drug administration. With computed tomography (CT) being one of the highest demand areas, 
contrast administration safety is one key consideration [1].  Although the risks associated with the use 
of low and iso-osmolar iodinated contrast media are considered marginal [2-8], there is a recognised 
causal link. The development of post contrast acute kidney injury (PC-AKI), defined as, an increase in 
serum creatinine of 1.5 times baseline, within 48-72 hours of intravascular administration of a contrast 
agent [9], is of particular relevance to patients with pre-existing kidney disease [10,11]. Despite the 
ongoing controversy, international guidelines still recommend the screening and risk stratification of 
patients prior to intravascular contrast administration [9,12-14]. 
Although the screening of kidney function by blood test is only advocated in those patients with risk 
factors, many organisations undertake a blanket screening or ‘test all’ strategy [15].  Within the 
outpatient radiology setting, Point of Care (PoC) blood testing has been suggested as a mechanism for 
kidney function testing prior to intravascular iodinated contrast media administration and these 
devices have been found to be a valid alternative to laboratory testing [16-25]. Although theoretically 
rapid laboratory result turnaround is possible, this depends on local provision and in practice is usually 
more than one hour and may not complement CT operations.  PoC testing, therefore potentially offers 
opportunities to reduce unnecessary investigations, reduce patient waits, speed up medical decision-
making and can promote improved operational efficiency and patient safety [1,16]. PoC analysis can 
be undertaken using a portable hand-held device. However, a range of alternatives are available on 
the market including benchtop (mini-lab/blood gas) analysers [25].  These allow testing in the 
radiology department immediately prior to the examination with the process owned by radiology, 
rather than the hospital laboratory. The benefits of PoC have been considered to be greatest where a 
screening questionnaire is used to identify patients with co-morbidities which may impair kidney 
function [23,24,26]. However, evaluation of the implementation of such initiatives within UK NHS 
clinical pathways is limited [15,25].  
This feasibility study has evaluated the viability of implementing screening procedures in conjunction 
with PoC creatinine testing in an outpatient CT service. The objectives included: assessment of 
individual patient risk factors; the availability of baseline pre-scan day blood test (as mandated locally); 
comparison of baseline and scan-day kidney function using estimated glomerular filtration rate (eGFR) 
categorisation; the technical practicalities associated with PoC testing, including failure rates; the 
clinical concordance of the PoC test against the laboratory gold standard; comparison of serum 
creatinine (SCr) result pre and post-contrast administration to identify potential PC-AKI.   
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MATERIALS AND METHODS 
Study setting 
This study was a prospective single centre (two UK acute hospital sites) feasibility study of PoC kidney 
function testing within CT.   
Study population  
Over an eight-week period between February and April 2017 consecutive adult outpatients (≥18 years) 
attending for a contrast-enhanced CT scan were approached (CT pathway including study specific 
procedures see Supplementary Figure 1). In advance, patients identified as potentially eligible from 
the radiology information system by a member of the research team, had been sent a study participant 
information sheet prior to their appointment. No upper age limit was adopted, but pregnant females 
and those unable to consent were excluded. As per local protocol at the time of the study, patients 
with a baseline eGFR below 60mL/min/1.73m2 followed the standard risk reduction regimen of oral 
hydration (1L at home) prior to the scan appointment, and all patients were advised to maintain 
hydration following discharge. Those who declined to participate proceeded straight to scan and 
followed the standard CT pathway. 
 
 
Study procedures 
Following written consent, all participants completed a screening questionnaire based on previous 
studies [23,24,27-29], as is the local standard of care. The questionnaire sought details of known 
kidney disease, diabetes, heart failure, hypertension, plus history of current/recent acute illness (in 
the last week, defined as diarrhoea and vomiting; flu; infection requiring antibiotic treatment or acute 
hospital admission). For the purposes of this feasibility study, the PoC test was performed as an 
adjunct to the local standard laboratory results (SCr and eGFR), which should have been obtained less 
than 3 months prior to the CT appointment, to comply with international guidelines [9]. Participants 
consented to have an additional PoC whole blood creatinine (WBCr) test and a standard laboratory 
SCr test performed on the day of the CT appointment. Contrast CT scan procedures followed standard 
clinical practice, utilising a standard or weight-based volume of intravenous contrast (iohexol; 
Omnipaque 350; GE Healthcare, Cork, Ireland) appropriate to the anatomy under investigation. All 
participants were also invited to attend for follow-up bloods tests analysed with the PoC device and 
in the hospital laboratory at 48-72 hours. PC-AKI was defined as an increase in baseline creatinine level 
of more than 50% (≥1.5 times baseline) [9]. Additionally we reviewed all cases where there was a 
relative increase in WBCr greater than 25% above baseline, enabling us to explore the characteristics 
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of any patient with acute deterioration in kidney function. Where appropriate, individuals meeting 
this lower threshold were reviewed by the medical team prior to discharge on the day of follow up.  
 
Blood sampling 
All patients were cannulated by a CT radiographer or clinical support worker (CSW) following local 
standard operating procedures and two whole blood samples were collected. One sample (S-
Monovette Lithium Heparin 2.7ml tube, Ref 05.1553, Sarstedt) was transported to the hospital 
laboratory for routine analysis. The other sample (1ml BD Plastipak syringe, Ref 303172, Becton 
Dickinson, San Agustin del Guadalix) was immediately tested on the PoC device within the CT scan 
suite.   
 
Test methods 
Laboratory serum samples were processed using Roche Modular IDMS calibrated enzymatic creatinine 
analysis on a Cobas8000 platform (Roche, Inc.). The CE-marked PoC analyser was the i-STAT (Abbott 
Laboratories), a handheld device in current use in UK imaging departments [14]. The device utilises an 
analytic cartridge system (i-STAT Crea, whole blood sample size 65µl) to reduce the risk of sample 
contamination. To avoid inter-device variation, a single analyser was used for the duration of the study 
at each site. To ensure the PoC device operated within the limits of acceptability for imprecision, daily 
quality assurance was performed during the research using the manufacturers’ quality control (QC) 
materials at two levels of creatinine concentration. Staff training for PoC device operation was 
provided and competency assessed through collaboration with the local PoC management team, the 
pathology department and manufacturer representative.   
 
Blood test results management 
Following cannulation and PoC testing patients proceeded straight to scan with CT contrast injection 
as appropriate for their examination. The exception being where the PoC test result identified a 
decline in kidney function from their baseline result, which prompted a requirement to wait for 
laboratory confirmation (detailed in the participant information sheet and consent procedure).   
 
The laboratory generated SCr and eGFR result were accessed from the hospital order communication 
system.  The Abbot i-STAT does not provide an eGFR calculation and therefore, for consistency, both 
laboratory and PoC eGFR values were derived from the creatinine measurements using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [30].   
 
Statistical Analysis 
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Data were transcribed into the EDGE research management system (University of Southampton) and 
exported to Microsoft Excel® for descriptive analysis.  
 
Scan-day creatinine and eGFR measures and the associated risk category (high risk =eGFR≤30; 
Moderate=eGFR31-44; Low≥45) [13] were compared and the results were also reviewed against the 
pre-scan (baseline) kidney function test. The clinical concordance between the baseline and scan-day 
results was evaluated through a modified Clarke Error Grid Analysis, a scatter plot of laboratory 
overlaid with eGFR results categorised into clinically relevant areas.  
Scan-day and follow up PoC WBCr measurements and the relevant laboratory SCr results were 
compared using Bland Altman analysis. Passing-Bablok regression was used to explore the presence 
of proportional and constant error (from the slope and intercept co-efficient, respectively). This 
approach does not assume that any measurement error in either the laboratory or PoC measurements 
is normally distributed. These were generated in R (The R Foundation) using the packages ‘mcr’ and 
‘BlandAltmanLeh’. 
 
 
RESULTS 
Following exclusions 300 participant samples were obtained for PoC and laboratory analysis (Figure 
1).  Of these, 102 patients voluntarily returned for a follow up blood test within the specified time 
frame. Additionally, a further 19 outpatients underwent a clinically required kidney function test 
through follow up clinics within one week of contrast administration.  
 
 
 
 
 
 
 
 
 
 
304 participants recruited 
57 declined 
1 excluded (duplicate scan request) 
Excluded 
1 unable to get blood 
1 lab sample haemolysed 
2 missing samples 
300 participants for analysis 
362 patients approached 
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Figure 1: Recruitment flow chart 
 
Participant characteristics  
The sample comprised 155 males (51.6%) and the mean age of participants was 65 years (range 23-91 
years). The cohort was predominantly Caucasian with only 1 (0.3%) Afro-Caribbean participant. The 
CT referrals originated from a number of different clinical specialities, including general surgery (n=82; 
27.3%), urology (n=52; 17.3%), oncology (n=49; 16.3%) and respiratory medicine (n=19; 6.3%). The 
majority of examinations related to the thorax and/or abdomen, with only 2 (0.7%) examinations 
restricted to the head and/or neck. 
 
Baseline blood test availability  
 
Although baseline blood tests were expected to be carried out within the 3 months prior to the scan 
appointment the actual timing varied, with a mean of 3.7 weeks (range 0 – 59.6 weeks), with 54.0% 
(n=162) of patients tested on the day of referral for the scan. Importantly, 12.3% (n=37) of blood tests 
referrals had to be initiated by the radiology department to ensure compliance with local screening 
procedures and to enable the scan to be performed within clinical pathway timescales. Despite these 
measures, 4 patients still presented for their scan appointment with no recent kidney function results 
available. All consented to study participation with 3 patients waiting for the laboratory result, the 
other patient was eventually scanned without contrast, as they could not wait for the laboratory test 
result. 
 
Scan day kidney function 
Only 14 patients (4.7%) had a scan-day laboratory eGFR below 45mL/min/1.73m2, with a single case 
meeting the high risk threshold of 30mL/min/1.73m2 (PoC test result 28mL/min/1.73m2). Importantly, 
this patient had a baseline laboratory eGFR of 70mL/min/1.73m2 performed seventeen days earlier 
but declared an acute illness in the preceding week on the screening questionnaire.  
 
102 follow up visit (34.0%) 
19 follow up bloods in clinic (6.3%) 
 
179 lost to follow up (59.7%) 
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The screening questionnaire identified all patients with an eGFR of <45mL/min/1.73m, although half 
of patients indicated at least 1 risk factor, with the most common being hypertension, followed by 
acute illness and diabetes (Figure 2). Due to the small number of high and moderate risk cases (eGFR 
≤30 or <45mL/min/1.73m) logistic regression was not performed. 
 
Figure 2. Risk factors (single and multiple) identified through the screening questionnaire 
 
Comparison of the scan-day and baseline laboratory eGFR results confirmed that the majority of 
patients (n=281/300; 93.7%) fell in the same risk category (Figure 3 and Table 1). For those 19 patients 
demonstrating a change in category, there was no significant difference in time interval between 
baseline and scan-day blood tests (whole cohort mean 29 days vs change 26 days; p=0.888). 
In 8 cases an increased risk was identified, with the scan-day eGFR result suggesting a moderate (or 
high) risk of PC-AKI, rather than low risk. In 11 cases the risk was considered to have reduced, including 
one whose kidney function was noted to have improved from 38mL/min/1.73m to 64mL/min/1.73m, 
supporting the decision to administer contrast. In one patient with known chronic kidney disease, the 
decision to withhold contrast was upheld despite a scan-day eGFR of 34mL/min/1.73m2 (PoC result 
32mL/min/1.73m2), the previous eGFR result being 29mL/min/1.73m2 obtained five days earlier. 
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Figure 3. Error grid comparing baseline (pre-scan) eGFR laboratory result to scan-day eGFR laboratory result 
(see table 1 for key) 
 
Table 1. Patient management implications of concordance between baseline (pre-scan) eGFR laboratory 
result and scan-day eGFR laboratory result  
Zone Implication if management based on pre-scan eGFR result No (%) 
A Same risk category – appropriate management 281 (93.7) 
B 
Changed from low risk to moderate risk, or vice versa. No impact on 
management (if all patients orally pre-hydrated as standard). 
17 (5.7) 
C 
Changed from being at high risk to either moderate or low risk,  
potential for unnecessary prophylaxis or withholding of contrast 
1 (0.3) 
D 
Incorrect classification and potential for increased risk of PC-AKI due 
to insufficient prophylaxis 
1 (0.3) 
Follow up blood test results 
The characteristics of the patients attending for follow up blood tests were similar to those observed 
in the whole cohort, with no significant difference in gender (p=0.644), age (p=0.533) and scan-day 
clinical risk category (p=0.602) based on laboratory eGFR result. Of the 121 patients who had a follow 
up blood test undertaken (study (n=102) or clinically initiated (n=19)), no instances of PC-AKI were 
demonstrated. A small number (n=5) of patients had an acute decline in kidney function, with >25% 
increase from the initial PoC WBCr level (Table 2). All had been administered 95ml of contrast, no 
other common demographic factors were identified. A number of these patients acknowledged (n=3) 
not following post-procedural hydration advice, no other attributable cause for the rise in creatinine 
was identified. 
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Table 2. – Characteristics of the patients identified with an increased level (>25%) of PoC whole blood 
creatinine (WBCr) post contrast administration. 
Age 
(years)/ 
gender 
Scan day 
WBCr 
(eGFR) 
Follow up 
WBCr 
(eGFR) 
% change 
in WBCr 
Interval 
(hrs) 
Examination 
performed 
68F* 75 (71) 101 (49) 34.7 48.5 CT head, chest, liver 
74F* 101 (47) 132 (34) 30.7 49.5 CT neck, chest, 
abdomen, pelvis 
74F* 82 (62) 107 (45) 30.5 75.5 CT colonography (inc. 
CT abdomen, pelvis) 
53F 41 (113) 55 (103) 34.1 72.5 CT Chest, abdomen, 
pelvis 
45M* 89 (90) 132 (56) 48.3 48.0 CT urogram 
Gender M=male; F=female 
*Patients referred to Ambulatory Care Unit, advised hydration and return (3 at 24hrs; 1 at 24 + 48hrs), kidney function 
improved on follow up bloods and patients discharged from hospital care. 
 
PoC performance 
The PoC analysis was performed by radiographers (clinical and/or research based) or support staff 
(Table 3), depending on staff availability. 
 
Table 3: Roles of the individuals performing the point of care analysis and number of test failures 
Role Scan day Follow up Total Number of 
failures n (%) 
Clinical Support Worker (CSW) (n=5) 43 32 75 1 (1.3) 
Radiographer (n=2) 24 19 43 3 (7.0) 
Researcher (n=3) 233 51 284 4 (1.4) 
Total 300 102 402 8 (2.0) 
 
Six test failures were recorded on the scan day for the Abbott i-STAT device, of these 2 related to an 
insufficient sample volume, 2 test cartridges were overfilled and 2 were due to an error with the 
cartridge itself. In relation to the follow-up tests, 2 failures were recorded, both due to the test 
cartridge being overfilled. All tests were successful on the second attempt.  
All QC tests fell within the limits set by the manufacturer. 
 
 
Concordance between the i-STAT and laboratory measures 
The average (mean) bias of the PoC device in relation to the laboratory standard was close to zero 
(Table 4 and Fig 4). The constant error between the Abbott i-STAT PoC scan-day measurements and 
the laboratory scan-day measurements was -3.71 (95% CI: -6.41 to -0.50) and the proportional error 
was 1.036 (95% CI: 1.00 to 1.07). 
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Table 4. Analysis for the Abbott i-STAT PoC device compared to the laboratory reference standard on scan day 
and at follow up 
 
Average Bias 
(95% CI) 
95% Limits of 
Agreement (95% CI) 
Correlation 
Coefficient 
(95% CI) 
Scan-day (n=300) 
-0.21 
(-1.01 to 0.58) 
-13.94  (-15.32 to -12.56) 
to 
13.51  (12.14 to 14.89) 
0.948 
(0.935 to  0.958) 
Follow up (n=102) 
-0.59 
(-1.81 to 0.63) 
-12.77 (-14.88 to -10.65) 
to 
11.59 (9.48 to 13.70) 
0.949 
(0.926 to 0.966) 
 
 
 
Figures 4A & B: Bland-Altman plots demonstrating the average bias of the Abbott i-STAT compared to 
laboratory measured serum creatinine measured on scan day (4A) and follow up (4B), including 95% levels 
of agreement.    
 
 
DISCUSSION 
Kidney function testing prior to intravascular 
contrast administration is only advocated for 
patients with identified risk factors [9,12-14]. 
However, the limited clinical history available 
to radiology, activity volumes and complex 
workflows mean pre-scan assessment of eGFR is the most common risk assessment technique 
[1,15,31]. Importantly, for centres which mandate a local pre-scan blood test screening procedure, a 
patient presenting without a current eGFR result may need to be rebooked, reducing scanner capacity 
and more importantly introducing a further delay to diagnosis and treatment.  
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There is no consensus on the optimal time interval between eGFR result and contrast media 
administration for stable outpatients; rather this should, in practice, be guided by clinical judgement 
based on the likelihood that kidney function has deteriorated significantly [25]. Patient safety remains 
of paramount concern and our results suggest that for a small number of patients a blood test result 
obtained in the weeks or months prior to contrast administration is not reliable. An appropriate 
decision may only be possible with scan-day screening and kidney function assessment; the 
implications of not considering a potential change in eGFR has already been highlighted in a UK 
Coroner’s inquest [32].  Our study has confirmed the validity of such a screening questionnaire to 
identify acute illness and co-morbidities linked to the increased risk of PC-AKI, similar to previous 
studies [23,26-29]. The high sensitivity, but relatively poor specificity of the tool to identify the small 
number of patients with radiology relevant kidney dysfunction is likely a factor of the broad questions 
used during this research study, and supports further modification to the questionnaire. Although 
screening promotes the identification of risk factors, without access to immediate blood test results 
this information is limited in its usefulness [26]. The results do confirm the potential for reducing 
inappropriate testing of patients with no risk factors.  
There remains controversy around the incidence of PC-AKI. However, it is widely acknowledged that 
the greatest risk is in patients with an eGFR ≤30mL/min/1.73m2, with 45mL/min/1.73m2consistently 
cited as a level above which the risk is very low or non-existent [4,11,13,14,33].  In our study there 
were no instances of PC-AKI, with only 5% demonstrating a rise in WBCr of greater than 25%. It is key 
to note that this small cohort of patients was not identified as high risk in pre-procedure screening, 
and although dehydration during the post-scan period was identified as an anecdotal contributor, it 
cannot be confirmed. This raises further questions as to whether centres are, or should be, advocating 
the maintenance of fluid intake, particularly post procedure. Although there is no strong evidence for 
the use of peri-procedural oral hydration in patients with a moderate risk of PC-AKI, this remains a 
common strategy in practice [15]. For centres where scan-day risk screening is in place and who opt 
for an oral hydration strategy for certain risk categories, it may be easier to provide hydration advice 
to all patients, where there are no contra-indications. Hydration prior to their CT scan appointment 
could avoid insufficient prophylaxis, or delays, at the appointment. In the absence of evidence, this 
may not be the most cost-effective approach, but does enable efficient workflow and maintenance of 
patient safety. 
The concordance of the study PoC device with the laboratory gold standard is consistent with other 
evaluations [16,17,23,24,34] and provides reassurance around the test results. Following appropriate 
training radiographers and support staff were able to undertake sample testing with a relatively low 
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failure rate, which appears to reduce with experience. These outcomes confirm that it is feasible to 
utilise a PoC device for kidney function screening in a radiology setting. 
Strengths 
This study has explored the clinical utility of a screening questionnaire in combination with PoC for 
risk stratification and evaluation of kidney function prior to intravenous contrast media 
administration. Additionally, monitoring for AKI post contrast administration (follow up) was offered 
to all participants and not restricted to patients with a baseline (pre-scan) reduced kidney function, a 
criticism of previous research. 
 
Limitations 
The low number of patients with pre-existing kidney dysfunction is in line with previous studies [17,26] 
and the stable out-patient population. This does however reinforce the need for a re-examination of 
the clinical pathway based on over-testing of patients. The study was limited to the review of a single 
PoC device in relation to test performance and failures, no other assessment of the practicalities 
associated with PoC use in clinical practice was evaluated. In this study PoC testing utilised a single 
portable hand-held device however, a range of alternatives are available on the market.   
The need for efficient workflow and rapid turn-around of referrals for contrast-enhanced imaging 
studies supports the introduction of PoC creatinine testing. However, due to previous concerns around 
the accuracy of the PoC creatinine technology, it is yet to make its way into mainstream use. This study 
has demonstrated that PoC creatinine testing is feasible within CT clinical pathways. Further evidence 
is required of the feasibility and practicality of embedding PoC technology into clinical practice 
through multi-centre evaluation on a much larger population.   
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